These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 29927785)

  • 1. Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
    Hoy JF; Richardson R; Ebeling PR; Rojas J; Pocock N; Kerr SJ; Martinez E; Carr A;
    AIDS; 2018 Sep; 32(14):1967-1975. PubMed ID: 29927785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV-Infected Adults on Tenofovir: A Randomized, Open-Label Study.
    Carr A; Kerr SJ; Richardson R; Ebeling P; Pocock N; Rojas J; Martinez E; Hoy J;
    J Bone Miner Res; 2019 Dec; 34(12):2192-2197. PubMed ID: 31361922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.
    McComsey GA; Lupo S; Parks D; Poggio MC; De Wet J; Kahl LP; Angelis K; Wynne B; Vandermeulen K; Gartland M; Cupo M; Aboud M;
    AIDS; 2018 Feb; 32(4):477-485. PubMed ID: 29239893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial.
    Boontanondha P; Nimitphong H; Musikarat S; Ragkho A; Kiertiburanakul S
    Curr HIV Res; 2020; 18(1):52-62. PubMed ID: 31906840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults.
    Grant PM; Kitch D; McComsey GA; Tierney C; Ha B; Brown TT
    HIV Clin Trials; 2015; 16(2):66-71. PubMed ID: 25872972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
    Glidden DV; Mulligan K; McMahan V; Anderson PL; Guanira J; Chariyalertsak S; Buchbinder SP; Bekker LG; Schechter M; Grinsztejn B; Grant RM
    J Acquir Immune Defic Syndr; 2017 Oct; 76(2):177-182. PubMed ID: 28639995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.
    Cotter AG; Vrouenraets SM; Brady JJ; Wit FW; Fux CA; Furrer H; Brinkman K; Sabin CA; Reiss P; Mallon PW;
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1659-66. PubMed ID: 23436922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study.
    Mwasakifwa GE; Amin J; White CP; Center JR; Kelleher A; Boyd MA
    HIV Med; 2020 Sep; 21(8):492-504. PubMed ID: 32573910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intramuscular depot medroxyprogesterone acetate accentuates bone loss associated with tenofovir disoproxil fumarate-containing antiretroviral therapy initiation in young women living with HIV (the BONE: CARE study): a prospective cohort study in Uganda.
    Kiweewa Matovu F; Kiwanuka N; Nabwana M; Scholes D; Musoke P; Glenn Fowler M; Beksinska ME; Pettifor JM; Brown TT;
    Lancet Glob Health; 2022 May; 10(5):e694-e704. PubMed ID: 35427526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone density, microarchitecture, and tissue quality after 1 year of treatment with tenofovir disoproxil fumarate.
    Güerri-Fernández R; Lerma-Chippirraz E; Fernandez Marron A; García-Giralt N; Villar-García J; Soldado-Folgado J; González-Mena A; Trenchs-Rodríguez M; Guelar A; Díez-Pérez A; Brown TT; Knobel H
    AIDS; 2018 Apr; 32(7):913-920. PubMed ID: 29424785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
    Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM;
    Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
    Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
    Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal changes in bone mineral density and trabecular bone score following yearly zoledronic acid infusion in postmenopausal osteoporosis-a retrospective-prospective study from southern India.
    Sooragonda B; Cherian KE; Jebasingh FK; Dasgupta R; Asha HS; Kapoor N; Thomas N; Paul TV
    Arch Osteoporos; 2019 Jul; 14(1):79. PubMed ID: 31321603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy.
    Kalayjian RC; Albert JM; Cremers S; Gupta SK; McComsey GA; Klingman KL; Fichtenbaum CJ; Brown TT; Taiwo BO;
    AIDS; 2018 Nov; 32(17):2517-2524. PubMed ID: 30134291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.
    Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Harris DR; Price G; Baker A; Meyer WA; Wilson CM; Hazra R; Kapogiannis BG; Mulligan K;
    Clin Infect Dis; 2018 Jan; 66(2):220-228. PubMed ID: 29020329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.
    Kasonde M; Niska RW; Rose C; Henderson FL; Segolodi TM; Turner K; Smith DK; Thigpen MC; Paxton LA
    PLoS One; 2014; 9(3):e90111. PubMed ID: 24625530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study.
    Han WM; Wattanachanya L; Apornpong T; Jantrapakde J; Avihingsanon A; Kerr SJ; Teeratakulpisarn N; Jadwattanakul T; Chaiwatanarat T; Buranasupkajorn P; Ramautarsing R; Phanuphak N; Sunthornyothin S; Ruxrungtham K; Phanuphak P;
    PLoS One; 2020; 15(3):e0230368. PubMed ID: 32210458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy.
    Darvishi-Khezri H; Kosaryan M; Akbarzadeh R; Aliasgharian A; Fazli M
    Med Arch; 2018 Jun; 72(3):170-173. PubMed ID: 30061760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone Mineral Density and Vitamin D Levels in HIV Treatment-Naïve African American Individuals Randomized to Receive HIV Drug Regimens.
    Cook PP; Stang AT; Walker LR; Akula SM; Cook FJ
    South Med J; 2016 Nov; 109(11):712-717. PubMed ID: 27812717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone turnover change after randomized switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIV.
    Moore AEB; Burns JE; Sally D; Milinkovic A; Krokos G; John J; Rookyard C; Borca A; Pool ERM; Tostevin A; Harman A; Dulnoan DS; Gilson R; Arenas-Pinto A; Cook GJR; Saunders J; Dunn D; Blake GM; Pett SL
    AIDS; 2024 Mar; 38(4):521-529. PubMed ID: 38061030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.